Autolus Therapeutics AUTL 深 滬
已收盤 07-02 16:00:00 美东时间
1.58
0.000
0.00%
華盛通- 最 高1.72
- 今 開1.60
- 成交量 144.26万股
- 最 低 1.565
- 昨 收 1.58
- 總市值 4.21亿
- 52周最高 2.70
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.175
- 委 比 -96.62%
- 總股本 2.66亿
- 歷史最高 53.24
- 量 比 1.76
- 振 幅 9.81%
- 歷史最低 1.105
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics granted stock options and RSUs to 13 employees under its 2025 Inducement Plan. The awards, totaling 25,420 ADS and 87,530 RSUs, were granted on June 24, 2026, with an exercise price of $1.66 per share. Options and RSUs vest over four years, contingent on continued employment. Autolus is a biopharmaceutical company developing next-generation T cell therapies for cancer and autoimmune diseases.
07-01 20:05
Autolus Therapeutics to Participate in Upcoming Investor Conference
Autolus Therapeutics will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. CEO Dr. Christian Itin will present in a Fireside Chat on June 30, 2026, at 9:00am EDT / 14:00pm BST. The webcast will be available on the Company’s website, with a replay archived for 90 days. Autolus is a biopharmaceutical company developing next-generation T cell therapies for cancer and autoimmune diseases.
06-25 11:00
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics appoints Robert Azelby to its Board of Directors. With over 30 years of biopharmaceutical leadership, Azelby brings expertise in oncology commercialization and corporate strategy. His addition coincides with the advancement of vopimetostat, a potential PRMT5 inhibitor for pancreatic cancer, toward late-stage development. Azelby's experience will support Tango's mission to transform care for patients with MTAP-deleted cancers.
06-22 20:05
Autolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics plc has been awarded the 2026 Prix Galien UK Award for Best Biotechnology Product, recognizing its innovative T cell therapies. The award, often compared to the Nobel Prize in biopharmaceutical research, was granted by a committee of UK healthcare experts. Dr. Martin Pule, founder of Autolus, expressed pride in the company's mission to translate scientific research into effective treatments for patients. Autolus specializes i...
06-12 08:00
Immunic Appoints Michael W. Bonney As Board Chairman
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
电话会总结 ｜ Autolus(AUTL)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Autolus业绩会实录，以下是2026年第一季度财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度净产品收入达到2,620万美元，较2025年同期的900万美元实现近三倍增长，增幅达191%。收入主要来自美国市场销售以及英国市场的早期销售贡献。 **盈利能力：** 公司首次实现正毛利率，毛利为160万美元，而2025年各季度均为亏损状态。销售成本为2,460万美元，较2025年同期的1,800万美元增长36.7%，主要反映AUCATZYL销售量增长带来的成本上升。 **净亏损情况：** 净亏损为7,160万美元，较
05-19 12:13
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday
TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.
05-19 00:33
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Autolus Therapeutics shares are trading lower. The company reported its Q1 financial results.
Autolus Therapeutics shares are trading lower. The company reported its Q1 fina...
05-14 23:25
Autolus Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
Autolus Therapeutics (NASDAQ:AUTL) released first-quarter financial results and...
05-14 21:42
